Accès à distance ? S'identifier sur le proxy UCLouvain
A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2006 |
| Language | Anglais |
| Conference | "11th Conference of the National-Osteoporosis-Society", Harrogate (England) (Jun 25-28, 2006) |
| Journal information | "Osteoporosis International : with other metabolic bone diseases" - Vol. 17, p. S31-S31 (2006) |
| Peer reviewed | yes |
| issn | 0937-941X |
| e-issn | 1433-2965 |
| Publisher | Springer London Ltd (Artington) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL |
| Links |
| Bibliographic reference | Reid, I. ; Devogelaer, Jean-Pierre ; Miller, P. ; Brown, J. ; Fraser, W. ; et. al. A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease.11th Conference of the National-Osteoporosis-Society (Harrogate (England), Jun 25-28, 2006). In: Osteoporosis International : with other metabolic bone diseases, Vol. 17, p. S31-S31 (2006) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/59403 |